Published in AIDS Weekly, September 11th, 2006
The guidelines were presented at the International AIDS Conference (IAC) in Toronto, Canada.
Lexiva is a protease inhibitor that was co-discovered by GlaxoSmithKline and Vertex Pharmaceuticals Incorporated (VRTX). It is indicated in combination with other antiretroviral agents for the treatment of HIV infection in adults. Lexiva was approved by the U.S. Food and Drug Administration...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.